The secret to staying young and rich

Forward to a Friend Having trouble viewing this issue? Click here. Refer a Friend to Energy and Capital.

The secret to staying young and rich By Jason Stutman | Monday, June 30th, 2014 “If you’re a wealthy guy and haven’t stored your stem cells, I think you’re a total idiot.” Those are the words of Dr. Lionel Bissoon, a New York City physician who makes a living serving Wall Street's elite. Bissoon's patients come to him complaining of common ailments of aging such as low energy, body fat, and decreased sex drive. These are wealthy and entrenched men seeking the figurative Fountain of Youth. Quite often, they're younger than you might expect. Brian Pasalich, Vice President of Emerald Financial, is just 38 and visits Dr. Bissoon twice a week. As one of Bissoon's services, Pasalich receives a regiment of testosterone injections. The whole practice might seem a bit eccentric at first, but Pasalich is adamant it works. “I had more energy. I was back to my old self. My mood was better. I was happier my sex drive was back and it helped my attitude... No doubt about it. When I was lower (testosterone), I was easily distracted. I felt drained and my energy was gone. Not as focused. For the first time in my life, I had started to see myself not as the young guy but as the experienced guy. You need energy to deal with things. Now, it’s easier for me to handle because I have the energy and focus to deal with it. This is like how you feel after a cup of coffee — you’re awake and can do anything!” But Dr. Bissoon only sees these treatments as a short-term solution. The true key to eternal youth, he believes, doesn't lie in testosterone replacement, but rather in stem cell therapy. Advertisement The Results Could Go Public Any Day Now... Phase II trial results of this new super treatment are set to break any moment. And this little company could conquer a $55 billion market. You could triple your money in one day... or hold on a bit longer and make gains of as much as 10,421%... or more. Because not only should this news have a short-term impact on the stock... It also promises to change the history of cardiac care forever. Go here for the urgent details. As a higher-end service, Bissoon and his team extract stem cells from patients while they're still young — before the cells are irreparably damaged. These stem cells are stored for a monthly fee on top of an initial $15,000 operation that, as you might expect, is not covered by the patient's insurance. Patients are willing to dish out the cash because they know one day those cells will be useful. Despite what many might think, these aren't nutjobs falling for some bogus treatment — these are powerful and intelligent men, well educated in the field of regenerative medicine. Self-Healing The reason Dr. Bissoon thinks you're an idiot if you're not storing your stem cells is quite simple: the modern approach to stem cell therapy is self-pluripotent. In other words, stem cell therapies are now being derived from adult stem cells taken from a patient's own body. The most commonly touted benefit of pluripotent stem cells is ethics. By separating itself from the quandaries of embryonic research, the adult stem cell industry has removed itself from any legitimate moral concerns. More important, though, are the medical benefits. Our immune systems are far less likely to reject stem cells derived from our own bodies, much in the way successful organ transplants require matching blood types. And just like with organ transplants, there's a shortage of stem cell donors due to the invasiveness of the procedure. By allowing patients to use their own cells, self-pluripotent therapies will solve this problem. This is why Bissoon and his patients are trading huge chunks of cash just for preemptive procedures. It's also why a growing number of development-stage biotechs are banking on entire pipelines of self-pluripotent therapies and why the stem cell market is heating back up. Advertisement Have You Heard of "Blue Light" Technology? It's a groundbreaking cancer screen system that could not only save your life but also make you a millionaire for as little as $5,000. In short, it's a simple device that makes cancer visible to the naked eye. (You can see it in action here.) That's why it's revolutionizing the cancer diagnostics industry. And one tiny company holds the patent to this technology. Click here to get the ticker symbol. This could be the most lucrative investment you will ever make. Regenerative Market On June 19, the market took note of yet another recent catalyst for development-stage stem cell companies. Interim results on a stem cell trial taking place at the Retina Foundation of the Southwest in Dallas, Texas were enough to send StemCells Inc. (NASDAQ: STEM) flying nearly 34% in a single trading session: The treatment, aimed at curing age-related blindness, showed a 65%-70% reduction in disease progression and no reported safety issues. Likewise, 57% of participants experienced improved vision despite a disease that typically results in progressive visual loss. To the casual observer, this kind of catalyst would seem highly unpredictable, but it's really just a matter of mapping out a calendar and keeping previous data on hand. Take one look at the preclinical trials for STEM's drug candidate, and it's clear the company was onto something big: Rats receiving STEM's neural stem cell candidate maintained nearly as much visual acuity as non-diseased rats and greatly diverged from groups that didn't receive the transplant. The results were clear enough for us to expect positive Phase I data from the start, but shares remained cheap until there was no question about it. When you consider the one-day 34% gain, it's obvious the market was greatly overestimating the level of risk here. Of course, even stronger than animal models is data from actual human trials. In a recent Phase I study of 31 patients, another stem cell company has shown the ability to reduce damaged heart tissue following a heart attack. With a Phase II data readout on this candidate expected in the second half of this year, investors are poised to bank gains off yet another stem cell catalyst. A full presentation on that can be found here. Turning progress to profits,    Jason Stutman  @JasonStutman on Twitter Energy and Capital's tech expert, Jason Stutman has worked as an educator in mathematics, technology, and science... Before joining the Energy and Capital team, Jason served on multiple technology development committees, writing and earning grants in educational and behavioral technologies. Jason offers readers keen insights on prominent tech trends while exposing otherwise unnoticed opportunities. I liked this article | I did not like this article Follow Energy and Capital on The Bottom Line Related Articles The Truth About Stem Cell Stocks Recent Advancements in Stem Cell Research Big Profits in Big Data Recently... Guaranteed 20-Year Revenue Stream The Road to a Million Barrels Blood, Sweat, and a Pioneer Conquering the Cline Shale Who Will Win the Exabyte Game?

This email was sent to ignoble.experiment@arconati.us . You can manage your subscription and get our privacy policy here. Energy and Capital, Copyright © 2014, Angel Publishing LLC, 111 Market Place #720, Baltimore, MD 21202. All rights reserved. No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. Energy and Capital does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question. Unauthorized reproduction of this newsletter or its contents by Xerography, facsimile, or any other means is illegal and punishable by law. Please note: It is not our intention to send email to anyone who doesn't want it. If you're not sure why you're getting this e-letter, or no longer wish to receive it, get more info here, including our privacy policy and information on how to manage your subscription.